| Literature DB >> 28486208 |
Muneer Ahamed1, Bala Attili1, Daisy van Veghel1, Maarten Ooms1, Philippe Berben1, Sofie Celen1, Michel Koole2, Lieven Declercq1, Juha R Savinainen3, Jarmo T Laitinen3, Alfons Verbruggen1, Guy Bormans4.
Abstract
MAGL is a potential therapeutic target for oncological and psychiatric diseases. Our objective was to develop a PET tracer for in vivo quantification of MAGL. We report [11C]MA-PB-1 as an irreversible MAGL inhibitor PET tracer. The in vitro inhibitory activity, ex vivo distribution, brain kinetics and specificity of [11C]MA-PB-1 binding were studied. Ex vivo biodistribution and microPET showed good brain uptake which could be blocked by pretreatment with both MA-PB-1 and a structurally non-related MAGL inhibitor MJN110. These initial results suggest that [11C]MA-PB-1 is a suitable tracer for in vivo imaging of MAGL.Entities:
Keywords: Biodistribution; MAGL; MJN110; PET imaging; [(11)C]MA-PB-1
Mesh:
Substances:
Year: 2017 PMID: 28486208 DOI: 10.1016/j.ejmech.2017.04.066
Source DB: PubMed Journal: Eur J Med Chem ISSN: 0223-5234 Impact factor: 6.514